ClinicalTrials.gg

Program

Amoxicillin

Also written as “amoxicillin”, “400 mg Amoxicillin + 57 mg Clavulanic Acid/ 5 ml” and “Amoxicillin Capsules”.

Its studies are mostly in Respiratory Tract Infections · Tonsillitis · Otitis Media · Sinusitis · Glossitis, Benign Migratory, led by 4 companies.

Furthest: phase 4, since May 15, 20149 company-led studies, 1 open or runningNext primary completion: Dec 2026 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline40 open or runningphase 4since May 15, 2014Jul 18, 2006none ahead
Sun Pharmaceutical Industries30 open or runningno phasesince Oct 22, 2008Oct 22, 2008none ahead
Biocodex11 open or runningphase 4since Apr 23, 2024Apr 23, 2024Dec 2026phase 4 · NCT06451913
deva-holding-a-s10 open or runningphase 3since May 12, 2010May 12, 2010none ahead

Also a collaborator on its studies: pricara-unit-of-ortho-mcneil-inc.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 18, 2006First study: phase 1 study in Respiratory Tract InfectionsNew to GlaxoSmithKlineGlaxoSmithKline · NCT00354965 · 52 enrolled · United States
  2. Oct 22, 2008Sun Pharmaceutical Industries's first studies: 3 no phase studies in HealthyNew to Sun Pharmaceutical IndustriesSun Pharmaceutical Industries · NCT00778661, NCT00778284, NCT00778050
  3. May 12, 2010deva-holding-a-s's first study: phase 3 study in Helicobacter Pylori InfectionNew to deva-holding-a-sdeva-holding-a-s · NCT01131026 · 60 enrolled · Turkey
  4. Sep 8, 2011Phase 1 study in Bacterial InfectionsGlaxoSmithKline · NCT01431989 · 28 enrolled · Brazil
  5. Jan 17, 2013Phase 1 study in Respiratory Tract InfectionsGlaxoSmithKline · NCT01772238 · 35 enrolled
  6. May 15, 2014Phase 4 study in Focal Infection, DentalGlaxoSmithKline · NCT02141217 · 472 enrolled · Malaysia, Philippines, Thailand and more
  7. Apr 23, 2024Biocodex's first study: phase 4 study in Erythema Chronicum MigransNew to BiocodexBiocodex · NCT06451913 · 120 planned · Slovenia

Ahead

  1. Dec 2026Primary completion: phase 4 study in Erythema Chronicum MigransBiocodex · NCT06451913

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Bacterial penicillin-binding protein inhibitor”ChEMBL 37, by rule

Studies

All 9 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06451913Erythema Chronicum Migrans · Slovenia4RecruitingBiocodexDec 2026120
NCT02141217Focal Infection, Dental · Malaysia, Philippines, Thailand and more4CompletedGlaxoSmithKlineDec 28, 2013472
NCT01772238Respiratory Tract Infections1CompletedGlaxoSmithKlineMar 30, 201135
NCT01431989Bacterial Infections · Brazil1CompletedGlaxoSmithKlineJun 11, 201128
NCT01131026Helicobacter Pylori Infection · Turkey3Completeddeva-holding-a-sAug 201160
NCT00778661Healthy · United States–CompletedSun Pharmaceutical IndustriesOct 200240
NCT00778284Healthy · United States–CompletedSun Pharmaceutical IndustriesOct 200240
NCT00778050Healthy · United States–CompletedSun Pharmaceutical IndustriesOct 200226
NCT00354965Respiratory Tract Infections · United States1CompletedGlaxoSmithKlineApr 2, 200752

How it is read

Names in the registry

  • “Amoxicillin”, 6 entries
  • “amoxicillin”, 4 entries
  • “400 mg Amoxicillin + 57 mg Clavulanic Acid/ 5 ml”, 2 entries
  • “Amoxicillin Capsules”, 1 entry
  • “Amoxicillin + Saccharomyces boulardii CNCM I-745”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.